Lonza Group AG (via Public) / Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial
01/18/2021 | Press release | Distributed by Public on 01/18/2021 12:19 Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for sickle cell disease Lonza to provide cGMP material supply of ARU-1801 for its use in a pivotal clinical study in the United States Quote from Palani Palaniappan, Chief Technology Officer, Aruvant Sciences: 'We are partnering with Lonza, one of the world's leadin...
Source: publicnow.com
